Castle Biosciences reported results from a prospective, multicenter study published in Future Oncology evaluating its DecisionDx-Melanoma integrated i31-SLNB result in 912 patients with T1–T4 cutaneous melanoma across 30 U.S. centers. Among patients who underwent SLNB, those with less than 5% predicted risk by i31-SLNB had a 3% observed SLN positivity rate. In the T1–T2a subgroup, SLN positivity was 2% in those with less than 5% predicted risk and 17% in those with greater than 10% predicted risk. In patients with a low-risk i31-SLNB result and at least two years of follow-up, 3-year recurrence-free survival was 98%. The company said the data will be discussed in a webcast scheduled for March 23, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603131102PRIMZONEFULLFEED9671730) on March 13, 2026, and is solely responsible for the information contained therein.